News
PHGE
0.6000
-0.46%
-0.0028
Weekly Report: what happened at PHGE last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at PHGE last week (0224-0228)?
Weekly Report · 03/03 09:36
BiomX Announces $12M Funding for BX004 Study
TipRanks · 02/27 15:57
Reported Earlier, BiomX Announced ~$12M Securities Offering To Fund BX004 Phase 2b Study For Cystic Fibrosis; Topline Results Expected Q1 2026
Benzinga · 02/26 17:22
Press Release: BiomX Announces a Series of -2-
Dow Jones · 02/26 13:00
Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
Dow Jones · 02/26 13:00
Weekly Report: what happened at PHGE last week (0217-0221)?
Weekly Report · 02/24 09:36
Weekly Report: what happened at PHGE last week (0210-0214)?
Weekly Report · 02/17 09:35
Weekly Report: what happened at PHGE last week (0203-0207)?
Weekly Report · 02/10 09:34
Weekly Report: what happened at PHGE last week (0127-0131)?
Weekly Report · 02/03 09:35
Weekly Report: what happened at PHGE last week (0120-0124)?
Weekly Report · 01/27 09:36
Weekly Report: what happened at PHGE last week (0113-0117)?
Weekly Report · 01/20 09:34
Weekly Report: what happened at PHGE last week (0106-0110)?
Weekly Report · 01/13 09:34
BiomX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/08 16:31
BiomX’s Potential in Diabetic Foot Osteomyelitis Treatment with BX211 Drives Buy Rating
TipRanks · 01/08 16:25
Weekly Report: what happened at PHGE last week (1230-0103)?
Weekly Report · 01/06 09:36
Weekly Report: what happened at PHGE last week (1223-1227)?
Weekly Report · 12/30/2024 09:34
Weekly Report: what happened at PHGE last week (1216-1220)?
Weekly Report · 12/23/2024 09:36
BiomX regains compliance with NYSE American's listing rule
Seeking Alpha · 12/16/2024 15:06
BiomX regains compliance with NYSE American continued listing standards
TipRanks · 12/16/2024 13:31
More
Webull provides a variety of real-time PHGE stock news. You can receive the latest news about Biomx Inc through multiple platforms. This information may help you make smarter investment decisions.
About PHGE
More
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).